80%Confidence
0Views
FDASource
2026-04-12Date
Summary
Macleods Pharma's Class II recall for subpotent Levothyroxine Sodium tablets suggests manufacturing quality failures, which could affect patient trust and market share in the competitive thyroid medication sector. This may trigger increased FDA oversight for the company's India-based manufacturing operations, potentially leading to supply chain disruptions.
Actionable: Evaluate exposure to Macleods Pharma and consider diversifying investments in generic thyroid medications due to potential supply issues.
AI Confidence: 80%
Data Points
firmMACLEODS PHARMA USA, INC
classificationClass II
statusOngoing
distributionNationwide
productLevothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: M
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now